Norbrook officially inaugurates it's newly upgraded sterile injectable manufacturing suite.

Norbrook is a leading global manufacturer of sterile injectable products and is committed to accelerating revenue growth in this business segment. Recently, the business was proud to officially open the newly upgraded sterile injectable manufacturing suite in it's Station Works factory in Newry, Northern Ireland. This factory is home to Norbrook's intramammary suspension production. Several of Norbrook's key sterile products including Bovaclox DC, Noroclox DC and Opticlox are manufactured at this facility. These products are critical in treating and preventing infections in livestock and pets. 

The project represents a £1.3 million investment in a custom-built modular cleanroom with new Heating, ventilation, and air conditioning (HVAC) facilities and other enhancements. Norbrook's Board of Directors and senior leadership team were in attendance to inaugurate the facility. These updates ensure our compliance with the latest EU GMP Annex 01 (the European Union's guidelines for the manufacturing of sterile medicinal products) standards, reinforcing our commitment to excellence in pharmaceutical manufacturing.

Norbrook officially opens their refurbished sterile manufacturing suite

Members of the Norbrook Board of Directors & Leadership Team officially inaugurate the suite